Moderna aur Merck ke shares aaj niche gire hain. Inki personalized melanoma vaccine ke naye trial results mein recurrence risk **42%** kam hua hai, jo market ki ummeedon se thoda kam hai.
Kya hua market mein?
Moderna aur Merck ke shares mein aaj achi khasi girawat dekhi gayi hai. News ye hai ki inki melanoma vaccine ke naye clinical data ne market ka dil tod diya hai. Investors ko lag raha tha ki results bahut strong aayenge, lekin reality thodi alag rahi.
Trial ke stats kya keh rahe hain?
Naye trial mein vaccine ne Keytruda ke saath milkar cancer recurrence risk ko 42% tak kam kiya, aur cancer ke failne ka khatra 38% kam hua. Problem ye hai ki purane, chhote trials mein ye numbers 49% aur 59% the. Investors ko lag raha tha ki bade trial mein performance aur behtar hogi, lekin yahan toh stats thode weak nikle.
Moderna aur Merck ka future daanv par?
Moderna ke liye ye project bahut bada test hai, kyunki unhe prove karna hai ki unki mRNA technology sirf COVID tak limited nahi hai. Agar ye technology cancer treatment mein fail hoti hai, toh future growth par sawal uth sakte hain.
Merck ke liye goal hai Keytruda ki dominance ko maintain karna. Ab market is result ko digest kar raha hai aur future trials par nazar tiki hai. Jab bhi aisi badi expectations miss hoti hain, stocks ka girna natural hai.